[Clinical and experimental studies on treatment postoperative gastric cancer with combined therapy of fuzhen huoxue anticancer prescription and chemotherapy].
Fuzheng Huoxue Anticancer prescription (FZHXAC) showed better clinical effect in treating 35 cases of postoperative patients with gastric cancer in middle or late stage as compared with 35 cases of controls. After treatment, the immune function of T-lymphocytes enhanced significantly, the hypercoagulability improved, the criteria such as OKT4/OKT8 ratio, antithrombase III (AT-III), fibrinolytic activity, etc were all normalized, the one year, 3 year and 5 year suvival rate of patient were elevated. FZHXAC showed obvious inhibitory action on tumor growth in nude mice with transplanted human gastric cancer, as compared with control, the difference was significant, P < 0.001. In comparing with chemotherapeutic drug 5-fluorouracil, FZHXAC showed no significant toxicity, it didn't influence the normal growth of body weight. These results suggested that FZHXAC could not only replenish the Zheng-Qi, improve blood circulation, improve immune function and extend the survival period of patient, but also might have direct inhibiting, killing action on gastric tumor cells, this problem is expecting for further research.
Shanghai Second Medical University.
A G
AG
Zhou
D W
DW
Huang
Y X
YX
Ding
D000328:Adult; D000368:Aged; D000818:Animals; D000990:Antithrombin III / Q000378:metabolism; D005743:Gastrectomy; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D011184:Postoperative Period; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate
D000990:Antithrombin III